Endothelial Glycocalyx as Biomarker for Cardiovascular Diseases: Mechanistic and Clinical Implications
- Authors
- Kim, Y.-H.; Nijst, P.; Kiefer, K.; Tang, W.H.W.
- Issue Date
- 2017
- Publisher
- Current Science Inc.
- Keywords
- Cardiovascular diseases; Endothelial glycocalyx; Syndecan-1 (sdc1)
- Citation
- Current Heart Failure Reports, v.14, no.2, pp.117 - 126
- Indexed
- SCOPUS
- Journal Title
- Current Heart Failure Reports
- Volume
- 14
- Number
- 2
- Start Page
- 117
- End Page
- 126
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/86099
- DOI
- 10.1007/s11897-017-0320-5
- ISSN
- 1546-9530
- Abstract
- Introduction: The endothelial surface layer is covered with abundant proteoglycans, of which syndecans and glycosaminoglycans are major constituents. Recent Findings: Among the endothelial glycocalyx (eGC) constituents, syndecan-1 (sdc1) is a main component, and an elevated serum level of sdc1 may indicate the degradation of eGC. In patients with ischemic heart disease or heart failure, elevation of serum sdc1 has been associated with worsening cardiac and renal function; however, the causal relationship between degradation of eGC and clinical outcomes is unclear. Summary: Herein, we review the previous literature on eGC in cardiovascular and noncardiovascular diseases and their clinical implications. © 2017, Springer Science+Business Media New York.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.